Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06439576
Status:
RECRUITING
Last Update Posted:
2024-07-10
First Post:
2024-05-28
Brief Title:
Real World Evidence in China Faricimab Use in Diabetic Macular Edema Retinal Vein Occlusion and Neovascular Age-Related Macular Degeneration The Farseeing Study
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
China Faricimab Real World Evidence Evaluation of Faricimab Effectiveness Safety and Treatment Pattern in Diabetic Macular Edema Retinal Vein Occlusion and Neovascular Age-Related Macular Degeneration The Farseeing Study
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The Farseeing Study will explore long-term effectiveness safety and treatment patterns among patients being treated with faricimab in real-world routine clinical practice in China It is a primary data collection non-interventional prospective and retrospective multi-center study designed to collect real-world long-term data to gain clinical evidence on faricimab by observing cohorts of patients with neovascular age-related macular degeneration nAMD diabetic macular edema DME and retinal vein occlusion RVO who are receiving treatment with faricimab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None